In‐vitro cyclosporin sensitivity of proliferating lymphocytes is predictive of in‐vivo therapeutic response in ulcerative colitis

The efficacy of cyclosporin in the management of ulcerative colitis is recognized. Not all patients respond to this treatment. Existing clinical and laboratory parameters are of little use in identifying those most likely to respond.

[1]  P. Truffa-bachi,et al.  The impact of immunosuppressive drugs on the analysis of T cell activation. , 2000, Current medicinal chemistry.

[2]  R. Ricketts.  Intravenous cyclosporin in ulcerative colitis: A five-year experience: R.D. Cohen, R. Stein, and S. B. Hanauer Am J Gastroenterol 94:1587–1592,(June),1999 , 2000 .

[3]  Carbonnel,et al.  Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis , 2000, Alimentary pharmacology & therapeutics.

[4]  C. Probert,et al.  Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes , 1999, Gut.

[5]  S. Hanauer,et al.  Intravenous cyclosporin in ulcerative colitis: a five-year experience , 1999, American Journal of Gastroenterology.

[6]  W. Stack,et al.  Short‐ and long‐term outcome of patients treated with cyclosporin for severe acute ulcerative colitis , 1998, Alimentary pharmacology & therapeutics.

[7]  K. Oka,et al.  Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine efficacy in psoriasis , 1998, Clinical pharmacology and therapeutics.

[8]  K. Oka,et al.  Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: Possible implications for individual therapeutic efficacy , 1997, Clinical pharmacology and therapeutics.

[9]  C. Corrigan,et al.  Inhibition of re-expression of surface CD4, but not CD8, on activated human T-lymphocytes by the immunosuppressive drugs dexamethasone and cyclosporine A: correlation with inhibition of proliferation. , 1996, International journal of immunopharmacology.

[10]  F. Casellas,et al.  Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. , 1995, Journal of clinical gastroenterology.

[11]  B. Li,et al.  The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. , 1994, The Journal of allergy and clinical immunology.

[12]  A. Hess.  Mechanisms of action of cyclosporine: considerations for the treatment of autoimmune diseases. , 1993, Clinical immunology and immunopathology.

[13]  A. B. Kay,et al.  Lymphocytes , 1991 .

[14]  A. Morita,et al.  Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment. , 1991, The Journal of investigative dermatology.

[15]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .